PTGX vs CRSP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PTGX Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Protagonist Therapeutics, Inc (PTGX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, PTGX trades at 36.9x Forward P/E with 58.6% operating margin (+5723.6% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, PTGX sits in CONSOLIDATION (3rd %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PTGX Revenue | CRSP Revenue | PTGX Op. Margin | CRSP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $0M | -136.7% | -5087.8% | PTGX |
| FY2019 | $0M | $290M | -34857.6% | 16.1% | CRSP |
| FY2020 | $30M | $0M | -225.4% | -49295.5% | PTGX |
| FY2021 | $30M | $910M | -460.0% | 40.8% | CRSP |
| FY2022 | $30M | $0M | -494.2% | -56190.4% | PTGX |
| FY2023 | $60M | $370M | -156.1% | -60.0% | CRSP |
| FY2024 | $430M | $40M | 58.2% | -1250.4% | PTGX |
| FY2025 | $50M | $0M | -343.6% | -18933.6% | PTGX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PTGX | CRSP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $8.7B | $4.1B | Larger Scale | PTGX |
| Trailing P/E Ratio Valuation | 28.1x | 23.4x | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 36.9x | 23.4x | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +5723.6% | +1325.1% | Higher Growth | PTGX |
| Operating Margin (TTM) Profitability | 58.6% | -2058.6% | Higher Margin | PTGX |
| Net Profit Margin Profitability | 62.0% | 0.0% | Higher Margin | PTGX |
| Return on Equity (ROE) Capital Efficiency | 39.6% | -25.6% | Higher ROE | PTGX |
| 52-Week Range Position Momentum | 58% ($77โ$161) | 1% ($40โ$63) | Stronger Trend | PTGX |
| Beta / 30D Volatility Risk Regime | 1.02ฮฒ ยท 35% Vol | 1.85ฮฒ ยท 60% Vol | Lower Realized Risk | PTGX |
| Unified Institutional Score Composite Signal | 32.6 / 100 (SELL) | 44.7 / 100 (HOLD) | Higher Composite | CRSP |